Korro Bio, Inc. announced the appointment of Rachel Meyers, PhD, to the company?s board of directors. Dr. Meyers is a seasoned biotechnology veteran whose experience in life sciences spans over two decades. Most recently, Dr. Meyers served as Chief Scientific Officer of Faze Medicines.

Previously, she was an Entrepreneur-in-Residence at Third Rock Ventures. Before that, Dr. Meyers held multiple leadership positions at Alnylam Pharmaceuticals for over 13 years, most recently as Senior Vice President of Research and RNAi Lead Development. Rachel completed her post-doctoral training at Harvard University and holds a PhD in Biology from the Massachusetts Institute of Technology and a BA in Biochemistry from Brandeis University.

Dr. Meyers was also appointed by the Board upon the recommendation of the NCG Committee to serve as a member of the Nominating and Corporate Governance Committee or NCG Committee.